WhichPepsPeptides. Without the hype.
GH secretagogue / appetite effects

GHRP-2 vs GHRP-6

Both are ghrelin-receptor agonist secretagogues; human literature is primarily physiology/endocrine research, not body-composition efficacy.

Evidence comparison table
AttributeGHRP-2GHRP-6
Human evidenceSmall human physiology studies show GH release, increased food intake and activation of ACTH/prolactin pathways.Small human studies characterize exposure and show route-dependent GH, ACTH/cortisol and sleep effects.
Research focusGH-axis physiologyGH-axis physiology
Regulatory statusNot FDA-approved; FDA highlights compounding safety uncertainty.Not FDA-approved; FDA highlights compounding safety uncertainty.
Route / formulationAcute hormone release does not prove body-composition or performance benefit.Pharmacokinetic and hormone responses do not establish clinical benefit.

Why these are compared

These compounds appear in the gh secretagogue / appetite effects evidence landscape, but they are not interchangeable. GHRP-2 is growth-hormone secretagogue hexapeptide studied in gh-axis physiology; GHRP-6 is growth-hormone secretagogue hexapeptide studied in gh-axis physiology. The purpose of this page is to compare the evidence base, not to recommend one compound over another.

Evidence maturity

GHRP-2: Limited human physiology / endocrine evidence; lifestyle efficacy unproven.

GHRP-6: Limited human pharmacology / endocrine evidence; clinical lifestyle efficacy unproven.

The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.

What this comparison can and cannot establish

No meaningful head-to-head outcome evidence identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.

No meaningful head-to-head outcome evidence identified Both are ghrelin-receptor agonist secretagogues; human literature is primarily physiology/endocrine research, not body-composition efficacy.